NASDAQ: CADL - Candel Therapeutics, Inc.

六个月盈利: +29.08%
部门: Healthcare

促销时间表 Candel Therapeutics, Inc.

先进的时间表 简单图表
Financial Markets by TradingView

关于公司

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma.

更多详情
It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is based in Needham, Massachusetts.
添加到比较列表
添加到观察列表
添加到投资组合
添加价格通知

Цена ао 1.49
Выручка 0.000125
EBITDA -0.0076
P/S 1829.26
P/BV 3.57
EV/EBITDA 0.6279
ISIN US1374041093
Сайт https://www.candeltx.com
Число акций ао 0.02894 млрд
Валюта usd
IPO date 2021-07-27
Sector Health Care
Industry Biotechnology
Валюта отчета usd
每日价格变化: -2.09% (6.71)
每周价格变化: -8.88% (7.21)
每月价格变化: +4.12% (6.31)
3个月内价格变化: +13.67% (5.78)
六个月内的价格变化: +29.08% (5.09)
每年价格变化: +606.45% (0.93)
3年内价格变化: -33.84% (9.93)
年初以来价格变化: +606.45% (0.93)
所有参数

低估

姓名 意义 年级
P/S 1064.07 1
P/BV 2.59 6
P/E 0 0
EV/EBITDA -0.5468 0
全部的: 3.5

效率

姓名 意义 年级
ROA, % -90.98 0
ROE, % -297.68 0
全部的: 0

股息

姓名 意义 年级
Div yield, % 0 0
DSI 0 0
全部的: 0

责任

姓名 意义 年级
Debt/EBITDA -0.5859 10
全部的: 9.8

成长冲动

姓名 意义 年级
盈利能力 Revenue, % -75.2 0
盈利能力 Ebitda, % 389.36 10
盈利能力 EPS, % 205.63 10
全部的: 8
更多详情

机构 体积 分享, %
Northpond Ventures, Llc 1935215 6.59
Sands Capital Ventures, LLC 811737 2.77
Vanguard Group Inc 425749 1.45
FMR, LLC 298384 1.02
Geode Capital Management, LLC 139253 0.47
Bridgeway Capital Management, Inc. 132595 0.45
Baystate Wealth Management LLC 76910 0.26
Blackrock Inc. 49285 0.17
OneDigital Investment Advisors LLC 29783 0.1
State Street Corporation 27600 0.09

ETF 分享, % 本年盈利能力, % 股息, %
ProShares Hedge Replication ETF 0.00093 5.9237999659878 1.47892
iShares Micro-Cap ETF 0.03787 36.318555985322 1.54048
iShares Russell 2000 Growth ETF 0.01119 38.042556988 0.6026
ProShares UltraPro Russell2000 0.00323 89.821266282945 1.47873
Vanguard Russell 3000 ETF 0 31.87314172448 1.43817
Vanguard Russell 2000 Growth ETF 0.01 39.350070246167 0.60264
Vanguard Russell 2000 ETF 0 35.648084105685 1.48801



导师 职称 支付 出生年份
Dr. Seshu Tyagarajan Ph.D. Chief Technical & Development Officer 335.27k 1968 (56 年)
Dr. Francesca Barone M.D., Ph.D. Chief Scientific Officer 506.76k 1978 (46 年)
Ms. Ileen B. Winick Chief People Officer N/A
Ms. Susan Stewart J.D., L.L.M. Chief Regulatory Officer N/A 1961 (63 年)
Dr. William Garrett Nichols M.D., M.S. Chief Medical Officer N/A 1969 (55 年)
Mr. Charles Schoch Interim CFO, Principal Accounting Officer, Treasurer & Secretary N/A 1985 (39 年)
Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. President, CEO & Director 1961 (63 年)

地址: United States, Needham. MA, 117 Kendrick Street - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://www.candeltx.com